![Bernd O. Wetzel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bernd O. Wetzel
Corporate Officer/Principal presso Atugen AG
Profilo
Bernd O.
Wetzel currently works at Atugen AG, as Member.
Dr. Wetzel also formerly worked at DeveloGen AG, as Deputy Chairman-Supervisory Board from 2009 to 2012, Silence Therapeutics Plc, as Non-Executive Director, Biovertis AG, as Director-Supervisory Board from 2009 to 2012, Biofrontera AG, as Member-Supervisory Board from 2011 to 2012, DIREVO Biotech AG, as Member-Supervisory Board, Ludwig-Maximilians-Universität München, as Professor, and Gruner Böhringer AG, as Chief Scientific Officer.
Posizioni attive di Bernd O. Wetzel
Società | Posizione | Inizio |
---|---|---|
Atugen AG
![]() Atugen AG Pharmaceuticals: MajorHealth Technology Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany | Corporate Officer/Principal | - |
Precedenti posizioni note di Bernd O. Wetzel
Società | Posizione | Fine |
---|---|---|
DeveloGen AG
![]() DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Direttore/Membro del Consiglio | 25/01/2012 |
SILENCE THERAPEUTICS PLC | Direttore/Membro del Consiglio | 05/01/2010 |
DIREVO Biotech AG
![]() DIREVO Biotech AG Miscellaneous Commercial ServicesCommercial Services DIREVO Biotech AG researches on screening-based directed evolution of genes and proteins and applies its integrated proprietary technologies to the development of biopharmaceuticals, industrial enzymes, chemical biocatalysts and enzymes for food and feed. Its platform technologies combine efficient DNA variation methods for mutation and recombination of genes with ultra-high throughput screening technologies. The company was founded in 2000 and is headquartered in Cologne, Germany. | Direttore/Membro del Consiglio | 25/10/2007 |
BIOFRONTERA AG | Direttore/Membro del Consiglio | - |
Ludwig-Maximilians-Universität München | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
SILENCE THERAPEUTICS PLC | Commercial Services |
BIOFRONTERA AG | Health Technology |
Aziende private | 5 |
---|---|
DeveloGen AG
![]() DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
Atugen AG
![]() Atugen AG Pharmaceuticals: MajorHealth Technology Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany | Health Technology |
Biovertis AG
![]() Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria. | Health Technology |
DIREVO Biotech AG
![]() DIREVO Biotech AG Miscellaneous Commercial ServicesCommercial Services DIREVO Biotech AG researches on screening-based directed evolution of genes and proteins and applies its integrated proprietary technologies to the development of biopharmaceuticals, industrial enzymes, chemical biocatalysts and enzymes for food and feed. Its platform technologies combine efficient DNA variation methods for mutation and recombination of genes with ultra-high throughput screening technologies. The company was founded in 2000 and is headquartered in Cologne, Germany. | Commercial Services |
Gruner Böhringer AG
![]() Gruner Böhringer AG Engineering & ConstructionIndustrial Services Gruner Böhringer AG engages in the provision of engineering and planning services. It specializes in the areas of infrastructure construction, hydraulic and sanitary engineering, geomatics, geology, and geographic information systems. The company was founded in 1952 and is headquartered in Oberwil, Switzerland. | Industrial Services |
- Borsa valori
- Insiders
- Bernd O. Wetzel